ABVC ABVC BIOPHARMA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1173313 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY234.3%
TTM net income YoY62.5%
TTM EPS YoY76.7%
Revenue 3-yr CAGR12.7%
Net income 3-yr CAGR—
Margins
Gross margin99.9%
Operating margin-850.7%
Net margin-773.6%
FCF margin—
EBITDA margin-840.1%
Returns
ROE-283.6%
ROA-51.4%
ROIC (approx.)-570.9%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets90.4%
Debt / equity0.00x
Current ratio0.33x
Interest coverage-5.25x
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | -$499,950 | $795,950 | — | — | $1,966 |
| Cost of revenue | — | — | — | — | — | — | — | $0 |
| Gross profit | — | — | — | — | $795,950 | — | — | $1,966 |
| R&D expense | $18,040 | $22,707 | $33,100 | $29,058 | $29,890 | $33,276 | $28,861 | $31,980 |
| SG&A expense | $376,946 | $503,778 | $751,998 | $783,640 | $798,253 | $690,094 | $615,371 | $488,420 |
| Operating income | -$1.24M | -$779,526 | -$1.57M | -$2.99M | -$1.96M | -$2.29M | -$693,005 | -$334,158 |
| Interest expense | $43,649 | $42,323 | $49,377 | $32,551 | $30,959 | $129,413 | $222,967 | $216,715 |
| Pretax income | -$1.39M | -$810,481 | -$1.69M | -$3.81M | -$2.08M | -$2.31M | -$944,190 | $128,943 |
| Income tax | — | — | — | $0 | $527 | $23,627 | — | $0 |
| Net income | $1.15M | -$736,934 | -$1.56M | -$3.56M | -$2.04M | -$2.26M | -$842,075 | $229,304 |
| EBITDA | -$1.23M | -$767,227 | -$1.57M | -$2.99M | -$1.94M | -$2.28M | -$685,984 | -$323,738 |
| EPS (basic) | 0.04 | -0.03 | -0.06 | — | -0.09 | -0.13 | -0.06 | — |
| EPS (diluted) | 0.04 | -0.03 | -0.06 | — | -0.09 | -0.13 | -0.06 | — |
| Weighted avg. shares (diluted) | 26.66M | 26.06M | 25.45M | — | 23.26M | 17.39M | 14.97M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11,294 | $31,944 | $140,324 | $681,480 | $192,068 | $1.08M | $759,568 | $863,815 |
| Short-term investments | $55,160 | $62,420 | $62,185 | $64,354 | $65,175 | $65,211 | $65,052 | $64,736 |
| Inventory | — | — | — | — | $11,460 | $11,460 | $11,460 | — |
| Current assets | $1.40M | $411,729 | $648,848 | $3.26M | $3.31M | $2.77M | $1.47M | $2.18M |
| PP&E, net | $12.83M | $12.83M | $12.82M | $12.84M | $12.85M | $8.22M | $8.17M | $511,088 |
| Total assets | $20.30M | $19.40M | $19.73M | $21.82M | $21.21M | $16.24M | $14.88M | $7.54M |
| Current liabilities | $7.19M | $5.69M | $5.39M | $6.92M | $6.54M | $6.53M | $6.73M | $6.56M |
| Short-term debt | $30,000 | $59,462 | $88,737 | $755,512 | $809,103 | $871,951 | $801,407 | $840,252 |
| Total liabilities | $8.55M | $7.13M | $6.90M | $8.52M | $6.72M | $6.75M | $6.92M | $6.82M |
| Shareholders' equity | $13.05M | $10.29M | $10.77M | $11.11M | $12.06M | $7.01M | $5.40M | $1.23M |
| Shares outstanding | 26.84M | 25.77M | 25.77M | 25.05M | 24.19M | 19.53M | 15.38M | 13.87M |
| Cash flow statement | ||||||||
| Operating cash flow | -$438,911 | -$244,413 | -$894,243 | -$1.42M | -$133,257 | -$894,174 | -$539,833 | -$493,611 |
| Investing cash flow | -$23,498 | -$101,531 | $47,123 | $730,346 | -$1.27M | — | — | — |
| Financing cash flow | $408,697 | $226,209 | -$342,181 | $1.15M | $1.13M | $1.93M | $428,756 | $581,456 |
| Depreciation & amortization | $6,906 | $12,299 | $5,783 | $5,791 | $25,330 | $13,718 | $7,021 | $10,420 |
| Stock-based compensation | $845,607 | $253,041 | $787,374 | $1.39M | $1.14M | $1.57M | $48,773 | $363,079 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.